Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

universities

Novartis building

Novartis skin cancer drug clears pivotal trial

Sonidegib achieves significant response in basal cell carcinoma patients

- PMLiVE

Servier signs cancer collaboration with Cellectis

Will target leukaemia and five solid tumours

Novartis building

Novartis enters PD-1 race via CoStim acquisition

Expands presence in cancer immunotherapies

- PMLiVE

Merck cuts MK-3475 deals with Pfizer, Amgen and Incyte

Sees combination potential for cancer prospect

- PMLiVE

Debunking cancer myths

World Cancer Day seeks to challenge preconceptions

- PMLiVE

Treatment alone will not tackle cancer epidemic, says WHO

Burden will be highest in developing countries

- PMLiVE

Servier expands breast cancer partnership

Will build on deal with French cancer research centre Curie-Cancer

- PMLiVE

Medigene buys cancer vaccine start-up

Acquires Trianta to boost immuno-oncology business

- PMLiVE

Going off-label?

There’s a thin line between the legitimate and fraudulent 'off-label' promotion, as a recent US court case highlights

- PMLiVE

Blow to Pfizer as dacomitinib fails in lung cancer trials

Unable to demonstrate improved survival in patients

Who tops the pharma list?

Chris Ross, with the help of healthcare analysts GlobalData, takes a New Year look at the past, present and future of global pharma, and asks: what’s trending? 

- PMLiVE

Merck shares jump on melanoma drug filing

MK-3475 could be approved by end of 2014

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links